EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Adverum Biotechnologies's Enterprise Value is $63.16 Mil.
Adverum Biotechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-112.51 Mil. Therefore, Adverum Biotechnologies's EV-to-FCF for today is -0.56.
The historical rank and industry rank for Adverum Biotechnologies's EV-to-FCF or its related term are showing as below:
ADVM'
s EV-to-FCF Range Over the Past 10 Years
Min: -21.91 Med: -0.5 Max: 3.77
Current: -0.56
During the past 13 years, the highest EV-to-FCF of Adverum Biotechnologies was 3.77. The lowest was -21.91. And the median was -0.50.
ADVM's EV-to-FCF is ranked worse than 100% of 410
companies
in the Biotechnology industry
Industry Median: 6.33
vs ADVM: -0.56
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Adverum Biotechnologies's EV-to-FCF
For the Biotechnology subindustry, Adverum Biotechnologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adverum Biotechnologies's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Adverum Biotechnologies's EV-to-FCF falls into.
Adverum Biotechnologies's current Enterprise Value is $63.16 Mil.
Adverum Biotechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adverum Biotechnologies's PE Ratio (TTM) for today is calculated as:
Adverum Biotechnologies's share price for today is $2.58.
Adverum Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Adverum Biotechnologies EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Adverum Biotechnologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADVM has been successfully added to your 